Segmentation, Major Trends, and Competitive Overview of the Anti-Inflammatory Drugs Market

The anti-inflammatory drugs sector is on track for substantial expansion as advancements in medical science and changing demographics continue to reshape the landscape. With increasing prevalence of autoimmune and chronic inflammatory conditions, this industry is expected to undergo significant growth and innovation, presenting new opportunities for treatment and market development.

Projected Market Size and Growth Trajectory of the Anti-Inflammatory Drugs Industry
The anti-inflammatory drugs market is anticipated to experience rapid growth in the coming years, reaching a value of $252.87 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 10.6%. Several factors are driving this surge, including breakthroughs in biologic therapies, greater adoption of biosimilars, the rising number of elderly individuals, an increase in autoimmune disorders, and the growing use of precision medicine approaches. Emerging trends expected to shape the market during this period include heightened utilization of biologics and biosimilars, broader treatment options for chronic inflammatory diseases, a shift toward more targeted anti-inflammatory treatments, growth in topical and localized drug formulations, and a stronger emphasis on long-term safety profiles.

Download a free sample of the anti-inflammatory drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24465&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Corporations Dominating the Anti-Inflammatory Drugs Market
Several prominent companies play a critical role in this market, such as Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Cipla Limited, Cadila Pharmaceuticals, Samsung Bioepis, and Lupin Limited.
A notable development occurred in October 2023 when Amgen, a US-based biopharmaceutical giant, acquired Ireland-based Horizon Therapeutics for approximately US$ 27.8 billion. This acquisition aims to enhance Amgen's portfolio in autoimmune and severe inflammatory diseases by incorporating Horizon's therapies such as TEPEZZA, KRYSTEXXA, and UPLIZNA. It also strengthens Amgen's foothold in the market for rare and chronic inflammatory conditions.

Innovations Shaping the Future of the Anti-Inflammatory Drugs Market
Top market players are investing heavily in next-generation corticosteroid alternatives to address the growing need for safer long-term anti-inflammatory treatment options. These novel therapies aim to offer the anti-inflammatory benefits of glucocorticoids while minimizing common side effects like bone loss, growth retardation, and weight gain.
For example, in October 2023, Santhera Pharmaceuticals, based in Switzerland, received approval from the US FDA for AGAMREE (vamorolone). AGAMREE is an oral dissociative steroid that selectively modulates glucocorticoid receptor pathways and stabilizes cell membranes, resulting in anti-inflammatory effects with fewer steroid-related adverse events. Compared to traditional corticosteroids such as prednisone and deflazacort, AGAMREE has a better safety profile while maintaining therapeutic efficacy. It is prescribed for managing chronic muscle inflammation in children aged two years and older with Duchenne muscular dystrophy.

View the full anti-inflammatory drugs market report:
https://www.thebusinessresearchcompany.com/report/anti-inflammatory-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Segmented Market Share and Forecast in the Global Anti-Inflammatory Drugs Industry
This report breaks down the anti-inflammatory drugs market into the following key segments:
1) Drug Class: Steroids, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Biologics and Biosimilars, and Other Drug Classes
2) Route of Administration: Parenteral, Oral, Topical, and Inhalation
3) Applications: Autoimmune Diseases, Respiratory Diseases, and Other Diseases
4) Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy

Further detailed subsegments include:
- Steroids: Corticosteroids and Mineralocorticoids
- NSAIDs: Non-Selective NSAIDs and Selective Cyclooxygenase-2 (COX-2) Inhibitors
- Biologics and Biosimilars: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin (IL) Inhibitors, Janus Kinase (JAK) Inhibitors, and other biologics and biosimilars
- Other Drug Classes: Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Immunosuppressants

This comprehensive segmentation highlights the diverse range of treatments and delivery methods that are central to the anti-inflammatory drugs market's ongoing growth and evolution.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.